75000 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 75010 - Statement - Condensed Balance Sheets link:presentationLink link:calculationLink link:definitionLink 75020 - Statement - Condensed Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 75030 - Statement - Condensed Statements of Operations and Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 75040 - Statement - Condensed Statements of Stockholders' Equity (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75050 - Statement - Condensed Statements of Cash Flows (Unaudited) link:presentationLink link:calculationLink link:definitionLink 75060 - Statement - Condensed Statements of Cash Flows (Unaudited) 2 link:presentationLink link:calculationLink link:definitionLink 995455 - Disclosure - Organization link:presentationLink link:calculationLink link:definitionLink 995465 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995475 - Disclosure - Fair Value Measurement and Marketable Securities link:presentationLink link:calculationLink link:definitionLink 995485 - Disclosure - Balance Sheet Components link:presentationLink link:calculationLink link:definitionLink 995495 - Disclosure - Operating Leases link:presentationLink link:calculationLink link:definitionLink 995505 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995515 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995525 - Disclosure - Common Stock link:presentationLink link:calculationLink link:definitionLink 995535 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995545 - Disclosure - Significant Agreements link:presentationLink link:calculationLink link:definitionLink 995555 - Disclosure - Revenue Recognition link:presentationLink link:calculationLink link:definitionLink 995565 - Disclosure - Net Loss Per Share Attributable to Common Stockholders link:presentationLink link:calculationLink link:definitionLink 995575 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 995585 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 995595 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 995605 - Disclosure - Fair Value Measurement and Marketable Securities (Tables) link:presentationLink link:calculationLink link:definitionLink 995615 - Disclosure - Balance Sheet Components (Tables) link:presentationLink link:calculationLink link:definitionLink 995625 - Disclosure - Operating Leases (Tables) link:presentationLink link:calculationLink link:definitionLink 995635 - Disclosure - Common Stock (Tables) link:presentationLink link:calculationLink link:definitionLink 995645 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 995655 - Disclosure - Revenue Recognition (Tables) link:presentationLink link:calculationLink link:definitionLink 995665 - Disclosure - Net Loss Per Share Attributable to Common Stockholders (Tables) link:presentationLink link:calculationLink link:definitionLink 995675 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink 995685 - Disclosure - Organization - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995695 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995705 - Disclosure - Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Details) link:presentationLink link:calculationLink link:definitionLink 995715 - Disclosure - Fair Value Measurement and Marketable Securities - Schedule of Financial Assets Measured and Recognized at Fair Value (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 995725 - Disclosure - Fair Value Measurement and Marketable Securities - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995735 - Disclosure - Balance Sheet Components - Summary of Property and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 995745 - Disclosure - Balance Sheet Components - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995755 - Disclosure - Balance Sheet Components - Summary of Accrued Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995765 - Disclosure - Operating Leases - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995775 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments under Operating Leases (Details) link:presentationLink link:calculationLink link:definitionLink 995785 - Disclosure - Operating Leases - Schedule of Future Minimum Lease Payments under Operating Leases (Details) 2 link:presentationLink link:calculationLink link:definitionLink 995795 - Disclosure - Operating Leases - Schedule Of Operating Lease Disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 995805 - Disclosure - Income Taxes - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995815 - Disclosure - Common Stock - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995825 - Disclosure - Common Stock - Schedule of Aggregate Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 995835 - Disclosure - Common Stock - Schedule of Aggregate Warrants (Parenthetical) (Details) link:presentationLink link:calculationLink link:definitionLink 995845 - Disclosure - Common Stock - Schedule of Number of Common Stock Reserved for Future Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 995855 - Disclosure - Stock-Based Compensation - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995865 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 995875 - Disclosure - Stock-Based Compensation - Summary of Activity under Plans (Details) link:presentationLink link:calculationLink link:definitionLink 995885 - Disclosure - Stock-Based Compensation - Assumptions Used to Calculate Fair Values of Options (Details) link:presentationLink link:calculationLink link:definitionLink 995895 - Disclosure - Significant Agreements - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995905 - Disclosure - Revenue Recognition - Summary of Changes in the Balance of Contract Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 995915 - Disclosure - Revenue Recognition - Summary of Transaction Price Allocated to the Remaining Performance Obligations (Details) link:presentationLink link:calculationLink link:definitionLink 995925 - Disclosure - Revenue Recognition - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995935 - Disclosure - Revenue Recognition - Additional Information (Details1) link:presentationLink link:calculationLink link:definitionLink 995945 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) link:presentationLink link:calculationLink link:definitionLink 995955 - Disclosure - Net Loss Per Share Attributable to Common Stockholders - Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share (Details) link:presentationLink link:calculationLink link:definitionLink 995965 - Disclosure - Segment Information - Summary Of Disaggregated Research And Development Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 995975 - Disclosure - Segment Information - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink 995985 - Disclosure - Subsequent Events - Additional Information (Details) link:presentationLink link:calculationLink link:definitionLink Other research and development expenses Other Research and Development Expense Milestone Payment Paid Milestone payment paid. Milestone payment paid Software Development [Member] Software Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Preferred Stock, Shares Issued Preferred stock, shares issued Preferred Stock, Shares Issued, Total Statement of Financial Position Location, Balance [Domain] Balance Sheet Location Increase (Decrease) in Accounts Payable Accounts payable Increase (Decrease) in Accounts Payable, Total Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Supplemental non-cash investing and financing activities: Two thousand fifteen and nineteen equity incentive plans and two thousand twenty three inducement plan. Two Thousand Fifteen and Nineteen Equity Incentive Plans and Two Thousand Twenty Three Inducement Plan [Member] 2015 and 2019 Plans and 2023 Inducement Plan Plan Name Plan Name [Axis] Entity Current Reporting Status Entity Current Reporting Status US Government Agencies Debt Securities [Member] U.S. Government Securities Operating Expenses [Abstract] Operating expenses Fair Value, Inputs, Level 2 [Member] Level 2 Significant agreements. Significant Agreements [Abstract] Commitments and Contingencies Disclosure [Text Block] Commitments and Contingencies Common Stock, Shares Authorized Common stock, shares authorized Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. [Member] Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Product and Service [Axis] Product and Service Exercise of outstanding options. Exercise Of Outstanding Options [Member] Exercise of Outstanding Options Document Fiscal Period Focus Document Fiscal Period Focus Revenue from Contract with Customer [Abstract] Entity Shell Company Entity Shell Company Other Accrued Liabilities, Current Other Segment Reporting, Policy [Policy Text Block] Segments Cash and Cash Equivalent Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value, Total Cash and Cash Equivalents, at Carrying Value, Beginning Balance Cash and Cash Equivalents, at Carrying Value, Ending Balance Milestone payment received clinical evaluation Milestone payment received clinical evaluation Milestone Payment Received Clinical Evaluation Milestone payment received clinical evaluation Subsidiary, Sale of Stock [Line Items] Subsidiary Sale Of Stock [Line Items] Marketable Securities Credit Related Gain Loss Marketable securities credit related gain (loss) Marketable securities credit related losses Common Stock, Shares, Issued Common stock, shares issued Common Stock, Shares, Issued, Total Asset Class [Domain] Statement [Table] Statement [Table] Glaxo Smith Kline. Glaxo Smith Kline [Member] GSK Restricted Cash, Noncurrent Restricted cash Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Right-of-use asset obtained in exchange for a new operating lease liability Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted-average grant-date fair value of options granted Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Percentage of fair value of the shares on the grant date Statement [Line Items] Statement [Line Items] Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Outstanding Options, Weighted-Average Exercise Price, Options expired Warrant [Member] Pre-funded Warrants Issued and Outstanding Warrant Entity Filer Category Entity Filer Category Liabilities and Equity Total liabilities and stockholders’ equity Pay for external third-party cost percentage. Pay for External Third-party Cost Percentage Pay for external third-party cost percentage Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Outstanding Options, Weighted-Average Exercise Price, Exercisable Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset Fair Value, by Balance Sheet Grouping [Table Text Block] Schedule of Financial Assets Measured and Recognized at Fair Value Cash and Cash Equivalents, Fair Value Disclosure Cash and cash equivalents, estimated fair value Shares Issued, Price Per Share Offering price per share Subsequent Event [Line Items] Subsequent Event [Line Items] Lease liabilities Increase (decrease) in operating lease liabilities. Increase Decrease In Operating Lease Liabilities Options to Purchase Common Stock Debt Securities, Available-for-Sale, Noncurrent Fair value Geographical [Domain] IDE574 [Member] IDE574. IDE574 Glaxo Smith Kline collaboration agreement. Glaxo Smith Kline Collaboration Agreement [Member] GSK Collaboration Agreement Additional Paid in Capital, Common Stock Additional paid-in capital Additional Paid in Capital, Common Stock, Beginning Balance Additional Paid in Capital, Common Stock, Ending Balance Common stock remained available to be sold Common Stock Remaining Available To Be Sale Amount Common stock, remaining available to be sale, amount. Significant Accounting Policies [Text Block] Summary of Significant Accounting Policies Property, Plant and Equipment [Line Items] Property Plant And Equipment [Line Items] Vesting [Domain] Vesting Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Outstanding Options, Shares, Options granted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Computation of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders Two thousand nineteen employee stock purchased plan. Two Thousand Nineteen Employee Stock Purchased Plan [Member] 2019 Employee Stock Purchase Plan Earnings Per Share, Basic Earnings Per Share, Basic, Total Net income (loss) per share attributable to common stockholders, basic Net loss per common share, basic Disaggregation of Revenue [Table Text Block] Summary of Revenue Disaggregated by Research Program Upfront payment. Upfront Payment Upfront payment Share-Based Payment Arrangement, Noncash Expense [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Outstanding Options, Shares, Ending balance Outstanding Options, Shares, Beginning balance Liabilities, Current Total current liabilities Increase (Decrease) in Accounts Receivable Accounts receivable Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract] Adjustments to reconcile net loss to net cash used in operating activities Revenue, Major Customer [Line Items] Aggregate purchase price of unvested restricted stock at a period end. Aggregate Purchase Price Of Unvested Restricted Stock Subject To Repurchase Aggregate purchase price of unvested restricted stock subject to repurchase Accounting Standards Update [Axis] Equity, Attributable to Parent [Abstract] Stockholders’ equity Entity Small Business Entity Small Business Share based compensation arrangement by sharebased payment award of shares outstanding percent. Share Based Compensation Arrangement by Sharebased Payment Award of Shares Outstanding Percent Shares outstanding under ESPP Retained Earnings (Accumulated Deficit) Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit), Total Retained Earnings (Accumulated Deficit), Beginning Balance Retained Earnings (Accumulated Deficit), Ending Balance Subsidiary or Equity Method Investee, Sale of Stock, Type [Table] Subsidiary Or Equity Method Investee Sale Of Stock By Subsidiary Or Equity Investee [Table] Yujiro S. Hata [Member] Yujiro S. Hata. Yujiro S. Hata Milestone payments relating to first and second tumor histologies. Milestone Payments Relating To First And Second Tumor Histologies Milestone payments relating to first and second tumor histologies Payments for achievement of specific development and regulatory approval events. Payments For Achievement Of Specific Development And Regulatory Approval Events Payments for achievement of specific development and regulatory approval events Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Outstanding Options, Shares, Options canceled Sale of Stock, Price Per Share Common stock offering price Servier License Agreement [Member] Servier license agreement. Servier License Agreement Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Aggregate intrinsic value of options exercised Incentive stock options. Incentive Stock Options [Member] Incentive Stock Options Share-Based Payment Arrangement [Text Block] Stock-Based Compensation Organization, Consolidation and Presentation of Financial Statements [Abstract] Leases [Abstract] Amendment Flag Amendment Flag Michael White [Member] Michael White. Michael White Product and Service [Domain] Products and Services Additional future aggregate total development milestones Eligible to Receive Additional Future Aggregate Development Milestones Eligible to receive additional future aggregate development milestones. Class of Warrant or Right, Number of Securities Called by Warrants or Rights Warrants to purchase shares of common stock Number of Shares subject to Outstanding Warrants Liabilities and Equity [Abstract] Liabilities and Stockholders’ Equity Entity Address, Postal Zip Code Entity Address, Postal Zip Code Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Net cash used in operating activities Common Stock [Member] Common Stock Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Outstanding Options, Weighted-Average Exercise Price, Options granted Lessee, Operating Lease, Liability, to be Paid, Year Three 2029 Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance San Diego, California. San Diego, California [Member] San Diego, California Entity Address, Address Line One Entity Address, Address Line One Change in accounting principle, accounting standards update, immaterial effect Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false] Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Assumptions Used to Calculate Fair Values of Options Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV Earnings Per Share [Abstract] Supplemental Cash Flow Information [Abstract] Supplemental disclosure of cash flow information: Development milestone payments of phase two relating to first and second tumor histologies. Development Milestone Payments Of Phase Two Relating To First And Second Tumor Histologies Milestone payments of phase two relating to first and second tumor histologies Other Liabilities [Member] Other Current Liabilities and Other Non-Current Liabilities Statement of Financial Position Location, Balance [Axis] Balance Sheet Location Investment Type [Axis] Investment Type At-the-market offering. At The Market Offering [Member] At-the-market Offering Right-of-use assets Operating Lease, Right-of-Use Asset Payments to Acquire Debt Securities, Available-for-Sale Purchases of marketable securities Additional area of space leased Operating Leases Additional Area Leased Operating leases additional area leased. Werner Helicase program. Werner Helicase Program [Member] WRN Program Werner Helicase Program Document Type Document Type Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Series B Redeemable Convertible Preferred Stock Series B Redeemable Convertible Preferred Stock [Member] Series B redeemable convertible preferred stock. Number of shares of common stock subject to repurchase at a period end. Shares Common Stock Subject To Repurchase Shares subject to repurchase Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative Entity Central Index Key Entity Central Index Key Risks and uncertainties. Risks And Uncertainties Policy [Text Block] Risks and Uncertainties Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Net increase in cash, cash equivalents and restricted cash Subsequent Event Type [Domain] Subsequent Event Type Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Potentially dilutive securities Balance Sheet Related Disclosures [Abstract] Common Stock, Par or Stated Value Per Share Common stock, par value Andres Ruiz Briseno [Member] Andres Ruiz Briseno. Andres Ruiz Briseno Accounting Standards Update [Domain] Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent, Total Other comprehensive income (loss) Proceeds from issuance of pre-funded warrants to purchase common stock, net of issuance costs Proceeds from Issuance of Warrants Share-Based Payment Arrangement, Tranche One [Member] Cliff Vesting Amortization of right-of-use assets Operating Lease, Right-of-Use Asset, Periodic Reduction Jiangsu Hengrui Pharmaceuticals Co., Ltd [Member] Jiangsu Hengrui Pharmaceuticals Co., Ltd. Jiangsu Hengrui Pharmaceuticals Co., Ltd Hengrui Pharma Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term Outstanding Options, Weighted Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum Expected volatility, maximum Debt Securities, Available-for-Sale, Amortized Cost Marketable securities, amortized cost Total potential milestone payments Aggregate Potential Milestone Payments Aggregate potential milestone payments. Debt Securities, Available-for-Sale Marketable securities, estimated fair value Debt Securities, Available-for-sale, Total Fair value measurements and marketable securities. Fair Value Measurements And Marketable Securities [Text Block] Fair Value Measurement and Marketable Securities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Issuance of common stock upon exercise of stock options, shares Outstanding Options, Shares, Options exercised Accrued Liabilities, Current Accrued liabilities Accrued liabilities Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items] Current Fiscal Year End Date Current Fiscal Year End Date Document Quarterly Report Document Quarterly Report Entity Address, State or Province Entity Address, State or Province Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Number of Shares Underlying Outstanding Restricted Stock Awards, Unvested, December 31, 2021 Number of Shares Underlying Outstanding Restricted Stock Awards, Unvested, March 31, 2022 Shares of restricted stock IDE849 [Member] IDE849. IDE849 Financial Liabilities Fair Value Disclosure Financial liabilities recognized at fair value Financial Liabilities Fair Value Disclosure, Total Preferred Stock, Shares Outstanding Preferred stock, shares outstanding Preferred Stock, Shares Outstanding, Beginning Balance Preferred Stock, Shares Outstanding, Ending Balance Comprehensive Income (Loss), Net of Tax, Attributable to Parent Comprehensive loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Marketable securities, gross unrealized gains Common Stock, Capital Shares Reserved for Future Issuance Number of common stock reserved for future issuance Common stock, initially reserved for issuance Effect of dilutive shares Incremental Common Shares Attributable to Dilutive Effect of Share-Based Payment Arrangements Geographical [Axis] Contract with Customer, Liability, Revenue Recognized Revenue recognized Reclassification to revenue, as the result of performance obligations satisfied Reclassification to revenue, as the result of performance obligations satisfied Pre-funded warrants exercised Pre funded warrants exercised. Pre Funded Warrants Exercised Marketable Securities, Current Short-term marketable securities Marketable Securities, Current, Total Novartis international pharmaceuticals limited. Novartis International Pharmaceuticals Limited [Member] Novartis International Pharmaceuticals Limited Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Summary of Stock-Based Compensation Expense Laboratory and Office Facilities Laboratory And Office Facilities [Member] Laboratory and office facilities. Stock Issued During Period, Value, Stock Options Exercised Issuance of common stock upon exercise of stock options Laboratory equipment. Laboratory Equipment [Member] Laboratory Equipment Collaborative Arrangement Disclosure [Text Block] Significant Agreements External clinical development expenses External Clinical Development Expenses External clinical development expenses. Cash cash equivalents and marketable securities. Cash Cash Equivalents And Marketable Securities Cash, cash equivalents and marketable securities Common stock subject to outstanding pre-funded warrants Exercised. Common stock subject to outstanding pre-funded warrants Exercised Common stock subject to outstanding pre-funded warrants exercised Subsequent Event Subsequent Event [Member] Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Outstanding Options, Shares available for Grant, Additional shares authorized Other Assets, Noncurrent Other non-current assets Other Assets, Noncurrent, Total Antidilutive Securities Antidilutive Securities [Axis] Class of warrant or rights issue date. Class Of Warrant Or Rights Issue Date Issue Date Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Outstanding Options, Shares, Options expired Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value Total fair value of stock vested Milestone Payment Received For Achievement Of Clinical Development Milestone. Milestone Payment Received For Achievement Of Clinical Development Milestone Milestone payment received for achievement of clinical development milestone Additional payment of development milestone to achieve Additional Payment Of Development Milestone To Achieve Additional payment of development milestone to achieve. AOCI Attributable to Parent [Member] Accumulated Other Comprehensive Income (Loss) Finite-Lived Intangible Assets, Major Class Name [Domain] Cash [Member] Cash Transaction Price Transaction price. Transaction price including the upfront payment and the estimated reimbursable program costs Lessee, Operating Lease, Option to Extend Operating lease, option to extend, description Preferred Stock, Value, Issued Preferred Stock, Value, Issued, Total Preferred Stock, Value, Issued, Beginning Balance Preferred Stock, Value, Issued, Ending Balance Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued and outstanding as of March 31, 2026 and December 31, 2025 Minimum [Member] Minimum [Member] Minimum Financial Instrument [Axis] Assets, Current [Abstract] Current assets South San Francisco, California South San Francisco California [Member] South San Francisco, California. Summary of significant accounting policies. Summary Of Significant Accounting Policies [Line Items] Summary Of Significant Accounting Policies [Line Items] Segment Reporting [Abstract] Liabilities, Current [Abstract] Current liabilities Shares, Outstanding Ending balance, shares Beginning balance, shares Lessee, Operating Lease, Renewal Term Operating lease renewal term Proceeds from ESPP purchase Proceeds from Stock Plans Commitments and Contingencies Commitments and contingencies (Note 6) Two thousand nineteen incentive award plan. Two Thousand Nineteen Incentive Award Plan [Member] 2019 Equity Incentive Plan 2019 Plan General and Administrative Expense [Member] General and Administrative Operating Lease, Liability Total operating lease liabilities Total operating lease liabilities Unpaid At The Market Offering Program Costs in Accrued Liabilities Unpaid At-the-market offering program costs in accrued liabilities. Unpaid at-the-market offering program costs in accrued liabilities Milestone payment received for achievement of initial preclinical development milestone. Milestone Payment Received For Achievement Of Initial Preclinical Development Milestone Milestone payment received for achievement of initial preclinical development milestone Milestone payment received for achievement of earlier preclinical development milestone Unaudited condensed financial statements. Unaudited Condensed Financial Statements [Policy Text Block] Unaudited Condensed Financial Statements Marketable Securities, Noncurrent Long-term marketable securities Marketable Securities, Noncurrent, Total Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Revenue from Contract with Customer, Product and Service [Extensible List] Early clinical development milestone payment potential to receive Early Clinical Development Milestone Payment Potential to Receive Early clinical development milestone payment potential to receive. Capital Expenditures Incurred but Not yet Paid Purchases of property and equipment in accounts payable and accrued liabilities Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total Contingent development and sales-based milestone payments Contingent development and sales based milestone payments. Contingent Development And Sales Based Milestone Payments Weighted Average Number of Shares Outstanding, Basic Weighted Average Number of Shares Outstanding, Basic, Total Weighted-average common shares outstanding, basic Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Outstanding Options, Aggregate Intrinsic Value, Exercisable Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Operating Leased Assets [Table] Long-Lived Tangible Asset Long-Lived Tangible Asset [Domain] Subsequent Events [Text Block] Subsequent Events APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Stock-based compensation APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total Equity, Attributable to Parent Ending balance Beginning balance Total stockholders’ equity Preferred stock, par value Preferred Stock, Par or Stated Value Per Share Basis of Accounting, Policy [Policy Text Block] Basis of Presentation Lessee, Operating Lease, Existence of Option to Extend [true false] Operating lease option to extend Statement of Stockholders' Equity [Abstract] Use of Estimates, Policy [Policy Text Block] Use of Estimates Over-Allotment Option [Member] Overallotment Option Leasehold Improvements [Member] Leasehold Improvements Entity Address, Address Line Two Entity Address, Address Line Two Marketable Securities Non Current [Member] Marketable securities non current. Marketable Securities Non-current Schedule of Accrued Liabilities [Table Text Block] Summary of Accrued Liabilities IDE892 [Member] IDE892. IDE892 Maximum number of shares purchasable by an employee under the ESPP per an offering period. E S P P Maximum Shares Purchasable Per Period Per Employee Maximum number of shares purchasable Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration] Plan Name [Domain] Plan Name Revenue, Performance Obligation Satisfied over Time [Abstract] Personnel Related And Stock-based Compensation Personnel related and stock-based compensation. Personnel related and stock-based compensation IDE397 IDE397 [Member] IDE397. Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis] Entity [Domain] Entity 2015, 2019 and 2023 Plans Two Thousand Fifteen, Nineteen and Twenty Three Equity Incentive Plans [Member] Two thousand fifteen, nineteen and twenty three equity incentive plans. Entity Address, City or Town Entity Address, City or Town Stock Repurchased During Period, Shares Common stock repurchased Repurchase of early exercised shares, shares Proceeds from Issuance of Common Stock At The Market Offering Program Net of Issuance Cost Proceeds from issuance of common stock at the market offering program net of issuance cost. Proceeds from issuance of common stock related to at-the-market offering program, net of issuance costs Number of Reportable Segments Number of reportable segments Security Exchange Name Security Exchange Name Property, Plant and Equipment, Gross Total property and equipment Property, Plant and Equipment, Gross, Total Property, Plant and Equipment, Gross, Beginning Balance Property, Plant and Equipment, Gross, Ending Balance Percentage of profit share. Percentage Of Profit Share Percentage of profit share Counterparty Name [Axis] Counterparty Name Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Outstanding Options, Shares, Vested and expected to vest Development milestone payments of phase three relating to first and second tumor histologies. Development Milestone Payments Of Phase Three Relating To First And Second Tumor Histologies Milestone payments of phase three relating to first and second tumor histologies Certain commercial sales milestones payment to be paid. Certain Commercial Sales Milestones Payment to be Paid Certain commercial sales milestones, agreed to make a payment Antidilutive Securities, Name [Domain] Antidilutive Securities, Name Investment Owned, Cost Amortized Cost Property plant and equipment useful life description. Property Plant And Equipment Useful Life Description Property and equipment net, useful life Stockholders' Equity Note [Abstract] Cash, cash equivalents and restricted cash Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation Cash, cash equivalents and restricted cash, at end of period Cash, cash equivalents and restricted cash, at beginning of period Interest Paid, Excluding Capitalized Interest, Operating Activity Cash paid for interest Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table] Statistical Measurement [Domain] Statistical Measurement Class of Warrant or Right, Exercise Price of Warrants or Rights Exercise Price per Share Assets, Current Total current assets Share-Based Payment Arrangement, Expense Total stock-based compensation expense Stock-based compensation expense Adjustments to Additional Paid in Capital, Exercise of Pre-Funded Warrants Adjustments to additional paid in capital, exercise of pre-funded warrants. Exercise of pre-funded warrants Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block] Summary of Transaction Price Allocated to Remaining Performance Obligations Document Period End Date Document Period End Date Title and Position [Axis] Title of Individual Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV Commercial Milestone Payments Commercial milestone payments. Commercial milestone payments Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Outstanding Options, Shares, Exercisable Statement of Financial Position [Abstract] Commercial milestone payment to be received. Commercial Milestone Payment To Be Received Commercial milestone payment eligible to receive Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Milestone payments of phase two relating to first and second tumor histologies Milestone Payments Of Phase Two Relating To First And Second Tumor Histologies Milestone payments of phase two relating to first and second tumor histologies. Operating Lease Commencement Month And Year Operating lease commencement month and year. Operating lease term commencement month and year Antidilutive Security, Excluded EPS Calculation [Table] Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table] Vesting [Axis] Vesting Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation [Abstract] Reconciliation of cash, cash equivalents and restricted cash Class of Stock [Axis] Pol Theta Program Polymerase Theta program. Polymerase Theta Program [Member] Liabilities Total liabilities Financial Instruments [Domain] Share-Based Compensation Arrangement by Share-Based Payment Award, Description Incentive award plan description Summary Of Disaggregated Research And Development Expenses Summary Of Disaggregated Research And Development Expenses [Table Text Block] Summary of disaggregated research and development expenses. Lessee, Operating Lease, Liability, to be Paid, Year Two 2028 Restricted Cash Restricted cash Restricted Cash, Total Restricted Stock [Member] Restricted Stock Indefinite-Lived Intangible Assets, Major Class Name [Domain] Indefinite-lived Intangible Assets, Major Class Name Weighted Average Number of Shares Outstanding, Diluted Weighted-average common shares outstanding, diluted Weighted-average shares used in computing net income (loss) per share attributable to common stock, diluted Weighted-average common shares outstanding,diluted Securities Act File Number Entity File Number OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Unrealized (losses) gains on marketable securities Unrealized (losses) gains on marketable securities ASU 2023-07 Accounting Standards Update 2023-07 [Member] Cover [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum Expected volatility, minimum Research and Development Services [Member] Research and development services . Research and Development Services Prepaid Expense and Other Assets, Current Prepaid expenses and other current assets Investments [Domain] Investments Supplemental Balance Sheet Disclosures [Text Block] Balance Sheet Components Additional milestone payment potentially received clinical evaluation Additional Milestone Payment Potentially Received Clinical Evaluation Additional milestone payment potentially received clinical evaluation Increase in number of shares available for issuance Share Based Compensation Arrangement by Share Based Payment Award Increase in Number of Shares Available for Issuance Share Based Compensation Arrangement by Share Based Payment Award Increase in Number of Shares Available for Issuance Represents information pertaining to the area leased. Operating Leases Area Leased Area of space leased US government agencies debt and corporate bond securities. U S Government Agencies Debt And Corporate Bond Securities [Member] U.S. Government Securities and Corporate Bonds Number of operating segments Number of Operating Segments Sale of Stock [Domain] Sale of Stock Segment Reporting Disclosure [Text Block] Segment Information General and Administrative Expense General and administrative General and Administrative Expense, Total Payment of option exercise fee Payment of Option Exercise Fee Payment of option exercise fee. Subsequent Event [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Shares issues under ESPP Common stock remain available Operating Leased Assets [Line Items] Increase in shares available for grant as a result of the number of shares under options that were cancelled during the reporting period. Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Cancelled In Period Outstanding Options, Shares available for Grant, Options canceled Issuance of pre-funded warrants to purchase common stock Adjustments to Additional Paid in Capital, Warrant Issued Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Outstanding Options, Weighted-Average Exercise Price, Vested and expected to vest Property, Plant and Equipment, Useful Life Property and equipment net, useful life New Accounting Pronouncements, Policy [Policy Text Block] Recent Accounting Pronouncements Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Schedule of Future Minimum Lease Payments under Operating Leases Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Contract with Customer, Liability, Current Short-term contract liability Contract liabilities, current Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Vesting period of options Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum Risk-free interest rate, minimum Net proceeds from issuance of common stock. Net Proceeds From Issuance Of Common Stock Proceeds from issuance of common stock net of underwriting discounts and commissions and other offering expenses Lessee, Operating Lease, Term of Contract Operating lease term Common Stock, Shares, Outstanding Common stock, shares outstanding Common Stock, Shares, Outstanding, Beginning Balance Common Stock, Shares, Outstanding, Ending Balance Operating Lease, Liability, Current Operating lease liabilities, current Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Depreciation, Depletion and Amortization Depreciation and amortization Depreciation, Depletion and Amortization, Total Research and Development Services Total transaction price allocated to the remaining performance obligations Revenue, remaining performance obligation, amount Document Transition Report Document Transition Report Operating Expenses Total operating expenses Research and Development Expense Research and development Research and Development Expense, Total Lessee, Operating Leases [Text Block] Operating Leases Statement of Cash Flows [Abstract] Stock Issued During Period, Value, New Issues Issuance of common stock, net of issuance cost Share-Based Payment Arrangement, Option, Activity [Table Text Block] Summary of Activity under Plans Two thousand twenty three inducement plan. Two Thousand Twenty Three Inducement Plan [Member] 2023 Inducement Plan Contract With Customer, Contract Liability, and Receivable [Table Text Block] Contract with customer, contract liability, and receivable. Summery of contract liabilities Equity [Text Block] Common Stock The discounted percentage of the fair market value of the Company's common stock for stock purchase in employee stock purchase plan. E S P P Discounted Purchase Price Percentage Percentage of the fair value of common stock Earnings Per Share [Text Block] Net Loss Per Share Attributable to Common Stockholders Computer Equipment Computer Equipment [Member] Net loss attributable to common stockholders Net loss Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Outstanding Options, Aggregate Intrinsic Value Development milestone payment to be received. Development Milestone Payment To Be Received Development milestone payment eligible to receive Operating Lease, Cost Operating lease cost Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Dividend yield Estimated dividend yield Operating Lease, Payments Cash paid included in measurement of operating lease liabilities included in cash flow from operating activities Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value Outstanding Options, Aggregate Intrinsic Value, Vested and expected to vest Assets [Abstract] Assets Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Risk-free interest rate Increase (Decrease) in Prepaid Expense and Other Assets Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets, Total Document Fiscal Year Focus Document Fiscal Year Focus Unvested early exercised common stock options. Unvested Early Exercised Common Stock Options [Member] Unvested Early Exercised Common Stock Options Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period Revenue, remaining performance obligation, expected timing of satisfaction, period Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract] Cash flows from investing activities Accounts Payable, Current Accounts payable Accounts Payable, Current, Total Amgen clinical trial collaboration and supply agreement. Amgen Clinical Trial Collaboration and Supply Agreement [Member] Amgen Clinical Trial Collaboration and Supply Agreement Research and Development Expense [Member] Research and Development Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Summary of Contract Balances Additional payments for achievement of specific development and regulatory approval events. Additional Payments For Achievement Of Specific Development And Regulatory Approval Event Additional payments for achievement of specific development and regulatory approval events Proceeds from Stock Options Exercised Proceeds from exercise of common stock options Fair Value Disclosures [Abstract] Commitments and Contingencies Disclosure [Abstract] South San Francisco South San Francisco [Member] South San Francisco. Lessee, Operating Lease, Liability, to be Paid, Year One 2027 Contract with Customer, Asset, after Allowance for Credit Loss, Current Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total Contract assets Incentive stock options and nonqualified stock options. Incentive Stock Options And Nonqualified Stock Options [Member] Incentive Stock Options and Nonqualified Stock Options Share-Based Payment Arrangement [Abstract] Sale of Stock [Axis] Sale of Stock Marketable securities remaining maturity period. Marketable Securities Remaining Maturity Period Marketable securities remaining maturity period Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Net cash provided by investing activities Milestone Payment Milestone payment. Milestone payment Title of 12(b) Security Title of 12(b) Security Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Outstanding Options, Weighted-Average Exercise Price, Options canceled Money Market Funds [Member] Money Market Funds Percentage of voting power of all classes of stock. Percentage Of Voting Power Percentage of voting power of all classes of stock Income Tax Disclosure [Text Block] Income Taxes Collaborative Arrangement and Arrangement Other than Collaborative [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year 2026 Legal Entity [Axis] Legal Entity Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract] Changes in assets and liabilities Property, Plant and Equipment [Table Text Block] Summary of Property and Equipment, Net Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Outstanding Options, Weighted-Average Exercise Price, Ending balance Outstanding Options, Weighted-Average Exercise Price, Beginning balance Income Tax Disclosure [Abstract] Fair Value, Recurring and Nonrecurring [Table] Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Additional Paid-in Capital [Member] Additional Paid-In Capital Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Accrued and other liabilities Share-based compensation arrangement by share-based payment award, options, additional shares authorized. Share Based Compensation Arrangement By Share Based Payment Award Options Additional Shares Authorized Outstanding Options, Shares, Additional shares authorized Statement of Income Location, Balance [Axis] Income Statement Location Change in Accounting Principle, Accounting Standards Update, Adoption Date Change in Accounting Principle, Accounting Standards Update, Adoption Date Development and regulatory milestone payment to be paid. Development and Regulatory Milestone Payment to be Paid Certain clinical and regulatory development milestones, agreed to make a payment Trading Symbol Trading Symbol Lessee, operating lease existence of option to renew. Lessee, Operating Lease Existence Of Option To Renew Operating lease existence of option to renew Effective Transition Period Effective transition period. Effective transition period Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum Risk-free interest rate, maximum ASU 2025-05 Accounting Standards Update 2025-05 [Member] Accounting Standards Update 2025-05. Subsequent Event Type [Axis] Subsequent Event Type Summary of Changes in the Balance of Contract Liabilities [Table Text Block] Summary of changes in the balance of contract liabilities. Summary of Changes in the Balance of Contract Liabilities Employee-related Liabilities, Current, Total Employee-related Liabilities, Current Accrued salaries and benefits Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract] Cash flows from financing activities Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Expected term Entity Ex Transition Period Entity Ex Transition Period Lessee, Operating Lease, Liability, to be Paid Total future minimum lease payments Lessee, Operating Lease, Liability, Undiscounted Excess Amount Less: imputed interest Less: imputed interest Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Maximum eligible rate of compensation Equity Components [Axis] Equity Components Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term Outstanding Options, Weighted Average Remaining Contractual Term (Years), Vested and expected to vest Shares Issued Weighted Average Sales Price Per Share Shares issued weighted average sales price per share. Weighted average sales price Nonoperating Income (Expense) Nonoperating Income (Expense), Total Interest income and other income, net Equity Component [Domain] Equity Component Asset Class [Axis] IDE034 [Member] IDE034. IDE034 MAT2A Program Methionine Adenosyl Transferase 2A program. Methionine Adenosyl Transferase2 A Program [Member] Maximum aggregate offering price at which the Company may offer and sell its common stock under the sales agreement. Sales Of Common Stock Aggregate Offering Price Sale of common stock aggregate offering price Development and regulatory milestone payment to be received. Development And Regulatory Milestone Payment To Be Received Eligible to receive development and regulatory milestone payments Employee stock purchase plan (ESPP) purchase, shares Stock Issued During Period, Shares, Employee Stock Purchase Plans Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Term of options Depreciation, Depletion and Amortization, Nonproduction Depreciation and amortization expense Depreciation, Depletion and Amortization, Nonproduction, Total Common Stock, Voting Rights Common stock, voting rights Share-based compensation arrangement by share-based payment award, number of shares available for grant, exercised in period. Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Exercised In Period Outstanding Options, Shares available for Grant, Options exercised Maximum [Member] Maximum Maximum Statistical Measurement [Axis] Statistical Measurement Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Outstanding Options, Weighted-Average Exercise Price, Options exercised Contract with Customer, Liability, Noncurrent Long-term contract liabilities Long-term contract liability Maximum share based compensation arrangement by share based payment award shares issued in period. Maximum Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Maximum shares issues under ESPP Receivables, Net, Current Accounts receivable Receivables, Net, Current, Total Common Stock, Value, Issued Common Stock, Value, Issued, Total Common Stock, Value, Issued, Beginning Balance Common Stock, Value, Issued, Ending Balance Common stock, $0.0001 par value, 300,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 87,856,154 and 87,796,561 shares issued and outstanding as of March 31, 2026 and December 31, 2025 Cash received for cost reimbursement. Cash Received For Cost Reimbursement Cash received for cost reimbursement Payment of one-time option exercise fee. Payment Of One Time Option Exercise Fee Payment of one-time option exercise fee Potential Aggregate Late Stage Development And Regulatory Milestones Potential aggregate late stage development and regulatory milestones. Potential aggregate late stage development and regulatory milestones Employee Stock Purchase Plan Employee stock purchase plan. Employee Stock Purchase Plan [Member] Follow-on public offering. Follow On Public Offering [Member] Follow On Public Offering Public Offering Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Expected volatility Preferred Stock, Shares Authorized Preferred stock, shares authorized Share-Based Payment Arrangement, Forfeiture [Policy Text Block] Share Based Compensation Forfeiture Finite-Lived Intangible Assets by Major Class [Axis] Operating lease commencement description. Operating Lease Commencement Description Operating lease commencement, description Revenue from Contract with Customer [Text Block] Revenue Recognition Entity Registrant Name Entity Registrant Name Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Marketable securities, gross unrealized losses Number of days of notice period for terminating collaboration agreement. Number Of Days Of Notice Period For Terminating Collaboration Agreement Number of days of notice period for terminating agreement Subsequent Events [Abstract] Cancer Research Technology and the University of Manchester [Member] Cancer Research Technology and the University of Manchester [Member] Cancer Research Technology and the University of Manchester Federal or state income tax provision Income Tax Expense (Benefit) Income Tax Expense (Benefit), Total Proceeds from issuance of common stock upon public offering, net of issuance costs Proceeds from Issuance of Common Stock Proceeds from issuance of common stock, net of issuance costs Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Concentration Risk, Credit Risk, Policy [Policy Text Block] Concentration of Credit Risk Accumulated Other Comprehensive Income (Loss), Net of Tax Accumulated Other Comprehensive Income (Loss), Net of Tax, Total Accumulated other comprehensive (loss) income IDE161 [Member] IDE161. IDE161 Accrued research and development expenses current. Accrued Research And Development Expenses Current Accrued research and development expenses Decrease in shares available for grant as a result of number of stock options granted during the period. Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Granted In Period Outstanding Options, Shares available for Grant, Options granted Payments to Acquire Property, Plant, and Equipment Purchases of property and equipment, net Payments to Acquire Property, Plant, and Equipment, Total Assets Total assets Property, Plant and Equipment [Table] Schedule Of Property Plant And Equipment [Table] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Outstanding Options, Weighted Average Remaining Contractual Term (Years), Exercisable Income Statement [Abstract] Total Milestone Payment To Be Received Total milestone payments Total milestone payment to be received. Fair Value Measurement and Marketable Securities Fair Value Measurements And Marketable Securities Policy [Text Block] Fair value measurements and marketable securities policy. Darovasertib [Member] Darovasertib. Darovasertib Summary of significant accounting policies. Summary Of Significant Accounting Policies [Table] Summary Of Significant Accounting Policies [Table] Issuance of common stock, net of issuance costs, shares Issuance of common stock, net of issuance costs, shares Issuance of common stock, net of issuance costs Earnings Per Share, Diluted Earnings Per Share, Diluted, Total Net income (loss) per share attributable to common stockholders, diluted Net loss per common share, diluted Title and Position [Domain] Title of Individual Dividends, Common Stock Common stock, dividends declared Dividends, Common Stock, Total Thereafter Lessee, operating lease, liability, to be paid, after year four. Lessee, Operating Lease, Liability, to be Paid, after Year Four Marketable Securities Current [Member] Marketable securities current. Marketable Securities Current City Area Code City Area Code Licensing Agreements [Member] License Agreement Lease Agreement Lease Agreements [Member] Amount of aggregate exercise price of early exercised shares of common stock at a period end. Aggregate Exercise Price Of Early Exercised Shares Common Stock Aggregate exercise prices of early exercised shares Counterparty Name [Domain] Counterparty Name Jefferies LLC. Jefferies L L C [Member] Jefferies LLC Variable Lease, Cost Variable lease cost Schedule of Revenue by Major Customers, by Reporting Segments [Table] The maximum offering period that could be set for the Employee Stock Purchase Plan. Share Based Compensation Arrangement By Share Based Payment Award Maximum Offering Period Maximum offering period under ESPP Employee stock purchase plan (ESPP) purchase Stock Issued During Period, Value, Employee Stock Purchase Plan Operating Lease, Weighted Average Remaining Lease Term Remaining Lease Term Upfront Fee Payment Upfront fee payment. Upfront fee payment Property, Plant and Equipment, Net Property and equipment, net Property and equipment, net Property, Plant and Equipment, Net, Beginning Balance Property, Plant and Equipment, Net, Ending Balance Corporate Bond Securities [Member] Corporate Bonds Operating Income (Loss) Loss from operations Accumulated Deficit Retained Earnings [Member] Share-Based Payment Arrangement, Noncash Expense Stock-based compensation Share-based Payment Arrangement, Noncash Expense, Total January two thousand twenty four sales agreement. January Two Thousand Twenty Four Sales Agreement [Member] January 2024 Sales Agreement Number of common stock voting rights held per share. Number Of Common Stock Voting Rights Held Per Share Number of common stock voting rights held per share Summary of Transaction Price Allocated to the Remaining Performance Obligations [Table Text Block] Summary of transaction price allocated to the remaining performance obligations. Summary of Transaction Price Allocated to the Remaining Performance Obligations Operating Lease, Weighted Average Discount Rate, Percent Discount Rate Operating Lease, Liability, Noncurrent Long-term operating lease liabilities Fair Value, Inputs, Level 1 [Member] Level 1 Class of Stock [Line Items] Class Of Stock [Line Items] Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Net cash provided by financing activities Change in Accounting Principle, Accounting Standards Update, Adopted [true false] Change in accounting principle, accounting standards update, adopted Lease expiration month and year. Lease Expiration Month and Year Lease expiration Pol Theta Helicase Inhibitor DC Pol Theta Helicase Inhibitor DC [Member] Pol theta helicase inhibitor DC member Estimated Fair Value Investments, Fair Value Disclosure Investments, Fair Value Disclosure, Total Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block] Schedule of Aggregate Warrants Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Schedule of Outstanding Shares of Potentially Dilutive Securities Excluded From the Computation of Diluted Net Loss Per Share PreclinicalDevelopmentMilestonePaymentPotentialToReceive Preclinical development milestone payment potential to receive. Preclinical Development Milestone Payment Potential to Receive Preclinical development milestone payment potential to receive Entity Interactive Data Current Entity Interactive Data Current Development costs sharing percentage. Development Costs Sharing Percentage Development costs sharing percentage Increase (Decrease) in Contract with Customer, Liability Contract liabilities Statement of Income Location, Balance [Domain] Income Statement Location Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract] Cash flows from operating activities Furniture and Fixtures [Member] Furniture and Fixtures Accretion (Amortization) of Discounts and Premiums, Investments Net accretion of discounts on marketable securities Balance as of December 31, 2025 Contract with Customer, Asset, after Allowance for Credit Loss Contract with Customer, Asset, after Allowance for Credit Loss, Total Balance as of March 31, 2026 Cash Equivalents, at Carrying Value Cash Equivalents, at Carrying Value, Total Cash and cash equivalents, amortized cost Entity Tax Identification Number Entity Tax Identification Number Share Price Share price Ten percent stockholder. Ten Percent Stockholder [Member] 10% Stockholder Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale Maturities of marketable securities Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Organization Schedule of common stock reserved for future issuance. Schedule Of Common Stock Reserved For Future Issuance Table [Text Block] Schedule of Number of Common Stock Reserved for Future Issuance Local Phone Number Local Phone Number Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Total unrecognized stock-based compensation expense for stock options Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Accounting Policies [Abstract] Revenue from Contract with Customer, Excluding Assessed Tax Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax, Total Numerator: Net Income (Loss) Attributable to Parent [Abstract] Lessee, Operating Lease, Liability, to be Paid, Year Four 2030 Cash and Cash Equivalents [Member] Cash and Cash Equivalents Class of Stock [Domain] Schedule of operating lease disclosures. Operating Leases Disclosures [Table Text Block] Schedule of Operating Lease Disclosures Commercial Paper [Member] Commercial Paper Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Outstanding Options, Shares available for Grant, Ending balance Outstanding Options, Shares available for Grant, Beginning balance Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Total unrecognized stock-based compensation expense, weighted-average period of recognition Accrued Professional Fees, Current Legal and professional fees Stock, Class of Stock [Table] Schedule Of Stock By Class [Table] Entity Emerging Growth Company Entity Emerging Growth Company Indefinite-Lived Intangible Assets [Axis] Indefinite-lived Intangible Assets President and CEO. President and CEO [Member]